Metagenomi
MGX | NASDAQ
$0.68
-$0.01 (-1.69%)
At close: Nov 16, 2026, 4:00 PM ET
$0.66
-$0.02 (-3.38%)
After-hours:
Nov 16, 2026, 6:18 PM ET
-1.69%
(1D)No price chart data available for 1D timeframe.
Rating
32
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #738/1021 (Top 72%)
Key Statistics
Market Data
Market Cap $25.71M
1D Range
0.66 0.71
52W Range
0.66 1.82
Valuation (TTM)
PE -0.27
PB 0.28
EV/EBITDA 0.44
Valuation (NTM)
Forward PE N/A
Forward PEG -0.10
Price Target $14.50
Cash Flow
FCF Yield -324.9%
SBC Adj. FCF Yield -361.1%
SBC Impact -11.1%
Margins
Gross Margin 69.5%
Operating Margin -1410.6%
FCF Margin -1178.8%
Growth (CAGR)
Revenue 3Y | 5Y -42.8% |
N/A
Dil EPS 3Y | 5Y -11.3% |
N/A
FCF 3Y | 5Y 12.9% |
N/A
Returns
ROA -59.9%
ROE -75.0%
ROIC -76.1%
Financial Health
Net Cash
$101.67M
Current Ratio 3.43
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sou...
Sector Healthcare
Industry Biotechnology
Employees 113
IPO Date Feb 9, 2024
Website www.metagenomi.co
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.56
Beat +12.43%
YoY:
-1.82% REV
$2.18M
Miss -15.18%
YoY:
-74.78%Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$14.50
Upside
+2032.35%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove MGX